



AGILENT TECHNOLOGIES

J.P. MORGAN 29TH ANNUAL HEALTHCARE CONFERENCE

JANUARY 10, 2011
WESTIN ST. FRANCIS
SAN FRANCISCO, CA



AGILENT TECHNOLOGIES

J.P. MORGAN 29TH ANNUAL HEALTHCARE CONFERENCE

DIDIER HIRSCH
SENIOR VICE PRESIDENT
CHIEF FINANCIAL OFFICER

This presentation contains forward-looking statements (including, without limitation, information and future guidance on our goals, priorities, revenues, demand, growth opportunities, customer service and innovation plans, new product introductions, financial condition, earnings, the continued strengths and expected growth of the markets we sell into, operations, operating earnings, and tax rates) that involve risks and uncertainties that could cause results of Agilent to differ materially from management's current expectations.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended October 31, 2010.

The company assumes no obligation to update the information in these presentations. These presentations and the Q&A that follows include non-GAAP numbers. A presentation of the most directly comparable GAAP numbers and the reconciliations between the non-GAAP and GAAP numbers can be found at <http://www.investor.agilent.com> under "Financial Results" and accompany this slide set.

THE WORLD'S PREMIER MEASUREMENT COMPANY

Electronic Measurement Group



FY10 Revenue: \$2.8B
FY10 Operating Margin* 16%

Ron Nersesian
President & GM

Chemical Analysis Group



FY10 Revenue: \$1.2B
FY10 Operating Margin* 23%

Mike McMullen
President & GM

Life Sciences Group



FY10 Revenue: \$1.5B
FY10 Operating Margin* 15%

Nick Roelofs
President & GM

FY10 Revenue \$5.5B, +19% organic growth Y/Y, 17% Operating Margin*
FY10 Non-GAAP EPS \$2.00*. Up from \$0.80* in FY09

*Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided.

Q4 2010 FINANCIAL HIGHLIGHTS

Orders = \$1.69B, +32% y/y (+23% organic)

Revenues = \$1.58B, +36% y/y (+26% organic):

LSG +35% y/y (+17% organic)

CAG +73% y/y (+17% organic)

EMG +23% y/y (+35% organic)

Cash Flow from Operations = \$367M

ROIC* = 24%

Operating Margin* = 19%

*Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided.

Revenue range = \$6.1B - \$6.3B

Y/Y revenue growth = total 12-15%, organic 6-10%

EPS* range = \$2.30 to \$2.50 per share

Cash Flow from Operations = \$950M

FY11 guidance is not being confirmed or updated at this time.

*Presented on a non-GAAP basis.

CASH AND CAPITAL STRUCTURE UPDATE

- \$1.5B World Trade debt paid back on Dec. 10, 2010
- Net cash & short term investments of \$598M* as of Oct. 31, 2010
- Share re-purchase to maintain basic outstanding share count of 346 million shares
- Priority uses of cash:
 - 1) Create value, invest organically and inorganically
 - 2) Return cash to shareholders through share purchases

*Presented on a non-GAAP basis. Reconciliation of net cash provided.

- On track to meet revenue and cost synergy targets
- Increased cost synergies to \$100M from \$75M, net of incremental investments in Varian R&D and Support
- Legal entities combined Nov. 1, 2010
- Employees transferred to Agilent entities and systems
- Customer facing processes, systems, and sales forces integrated Nov. 1, 2010
- Varian to be at Agilent tax rate by end of 2011

HOW WE WIN

Market reach and customer trust

- 6,000 sales and marketing employees supporting customers in over 100 countries
- #1 customer loyalty ranking in every major product category*
- 37% of Agilent revenue from Asia Pacific in Q4'10



Technology leadership

- \$600M/year, 11% Revenue invested in R&D, 2,600 researchers to ensure technology leadership
- Highest performing Oscilloscopes, Sources & Signal Analyzers, Network Analyzers, Liquid and Gas Chromatographs, and Mass Spectrometers



Scale

- Among the lowest instrument cost of sales in the industry
- Purchasing and infrastructure leverage



Team

- Employee satisfaction top quartile
- Well below average industry turnover




All built on Agilent's operating model

*Source: Lieberman Research Worldwide


GLOBAL SCALE AND SCOPE

Global revenue and operational footprint offers unmatched coverage and hedges risk

Revenue by Geography Q4'10



Headcount by Geography Q4'10




- Natural currency hedge through global revenue and operations
- Large Manufacturing and Admin presence in low cost regions driving operational excellence
- Broad distribution of R&D talent provides technology leadership worldwide
- Investment in sales & support focused on fast growing markets such as China and India

AGILENT REVENUE DISTRIBUTION BY END MARKET

\$41B Measurement Market Opportunity

FY 2010 Agilent Revenue



Markets	Size (\$B)	Growth
Life Sciences	19	5% - 7%
Chemical Analysis	10	5% - 6%
Electronic Measurement	12	4% - 5%
Total Market	41	5% - 7%

*Provided on a best estimate basis. November 2009 through October 2010.

FY 2011 PRIORITIES

ORGANIC GROWTH



- Outpace competitors' growth on an organic basis
- Develop differentiable solutions through technology leadership
- Capture emerging market opportunities

VARIAN VALUE CAPTURE



- Maintain focus on customer
- Drive revenue synergies
- Realize cost synergies
- Drive technology sharing between divisions and groups

LIFE SCIENCES INVESTMENT



- Invest in sample preparation solutions
- Expand academic and government market coverage
- Build NMR market position




AGILENT TECHNOLOGIES

J.P. MORGAN 29TH ANNUAL HEALTHCARE CONFERENCE


NICK ROELOFS
PRESIDENT,
LIFE SCIENCES GROUP

Q4'10 SEGMENT REVENUE DISTRIBUTION BY GEOGRAPHY


Agilent




LSG



CAG



EMG



LIFE SCIENCES MARKET OVERVIEW

Pharma/Biotech (For Profit)



14% of Agilent revenue

Academic and Government (Not-For-Profit)



7% of Agilent revenue

Market Size: \$19B
Growth: 5-7%

Growth Drivers

- Academic and government investment
- Life Science applications – “omics”
- Growth in generics, developing economies
- Therapeutic conversion to New Biological Entities

Key Competitors

- Thermo Fisher
- Waters
- Danaher
- Bruker
- LIFE

(1) Market size and growth data per Company estimates

(2) Percentages of Agilent revenue based on FY 2010 published revenues

1200 Infinity Liquid Chromatography Series

- The 1200 Infinity Series includes the new Agilent 1220 Infinity LC, the new Agilent 1260 Infinity LC and the enhanced Agilent 1290 Infinity LC
- 1290 offers the industry largest power range (1200bar, 5ml/min) for highest speed and resolution and 2-80x increased sensitivity



OpenLAB

- Scalable, open architecture, that enables you to easily capture, analyze, and share scientific data throughout the lab and across the enterprise
- Accelerates R&D efforts; optimizes lab processes; provides means to integrate disparate information systems; enhances existing workflows; secures IP; reduces regulatory risk



SureSelect™ XT Target Enrichment System

- The first fully customizable liquid genome partitioning / enrichment system
- Automates and enhances nucleic acid sequencing experiment when used in front of “next generation” sequencing technologies



6490 Triple Quad LC/MS System

- Breakthrough tenfold sensitivity increase over previous models
- Revolutionary iFunnel Technology atmospheric pressure ion sampling drives sensitivity
- Occupies 25% less bench space



LIFE SCIENCES – NEW PORTFOLIO

BRINGING NEW CAPABILITIES TO OUR CUSTOMERS

- NMR
- MRI
- X-Ray
- Prep HPLC
- Dissolution



NMR Family



7T Active Shield Human MRI



SuperNova – X-Ray Diffractometer



PrepStar SD1 Preparative HPLC



708DS - Dissolution System

All backed by our top-rated customer service and support

Grow market share

- Deliver the leading-edge application solutions customers demand
- Drive emerging application trends
- Leverage strong global presence to expand in developing geographies



Strengthen technology base

- Develop breakthrough products and technologies
- Lead new technology restatement and market creation
- Excel in customer service and support



Leverage Agilent's breadth and scale

- Incorporate leading edge electronics in our instrumentation
- Enhance value via Agilent's global manufacturing strength
- Invest in R&D for new technology development



CHEMICAL ANALYSIS MARKET OVERVIEW

Chemical &
Energy Testing



12% of Agilent
revenue

Environmental
Testing



8% of Agilent
revenue

Food
Testing



6% of Agilent
revenue

Forensics &
Drug Testing



2% of Agilent
revenue

Market Size: \$10B
Growth: 5-6%

Growth Drivers

- Food safety
- China and developing countries
- Lab productivity
- Replacement market

Key Competitors

- PerkinElmer
- Shimadzu
- Thermo Fisher
- Bruker

(1) Market size and growth data per Company estimates


(2) Percentages of Agilent revenue based on FY 2010 published revenues

High-end Mass Spec – GC-QQQ and ICP-MS

- GC-QQQ 7000B
- ICP-MS – Model 7700
- MassHunter SW – Making MS operation easier from tuning to final report



GC-QQQ 7000B



MassHunter Software

5975T LTM GC-MSD

- Industry's first laboratory quality performance transportable GC-MS
- Utilizes new patented low power, high efficiency low thermal mass technology (LTM)



5975T LTM GC-MSD

Enhance the Mid Range

- 7820A GC now on Chemstation & EzChrom
- New 5975E GC-MS
- New 7700E ICP-MS



7700E ICP-MS



5975E GC-MS

7696 Sample Prep Workbench


- Automating Sample Preparation for GC and LC
- Workflow solution for chromatography



7696 Sample Prep Workbench

Agilent MS Analyzed Vials

- Vials and Closures analyzed by GC/MS and LC/MS
- High-purity validated supplies ship with MS spectra



MS Analyzed Vials

LC Columns (SEC, Ion Exchange) for Biological Samples

- Batch to batch reproducibility for the most reliable separations
- Unique hydrophilic coatings improve separations of monoclonal antibodies, proteins, peptides and other bio-molecules

Agilent Bio SEC, IEX and MAB columns



TurboMolecular Pump Portfolio

- New compact, low power, higher performance designs based on new Twistorr molecular-drag technology



Turbo-V 850 Twistorr

CHEMICAL ANALYSIS – NEW PORTFOLIO

BRINGING NEW CAPABILITIES TO OUR CUSTOMERS

- Spectroscopy
- Consumables
- Mass Spec
- Vacuum



720 ICP-OES



490 Micro GC



Columns and Supplies



Ion Pump



VS Series MS He Leak Detector



GC-MS (Ion Trap)

All backed by our top-rated customer service and support

STRATEGY TO WIN – CHEMICAL ANALYSIS

Strengthen the core

- Sustain technology leadership
- Strengthen industry-leading customer satisfaction and loyalty
- Expand applications portfolio

Outgrow the market

- China
- Food testing
- Consumables
- High-End Mass Spec



Deliver the Varian value

- Increase market penetration in Asia
- Invest to build spectroscopy leadership
- Improve margins

FY 2011 PRIORITIES

ORGANIC GROWTH



- Outpace competitors' growth on an organic basis
- Develop differentiable solutions through technology leadership
- Capture emerging market opportunities

VARIAN VALUE CAPTURE



- Maintain focus on customer
- Drive revenue synergies
- Realize cost synergies
- Drive technology sharing between divisions and groups

LIFE SCIENCES INVESTMENT



- Invest in sample preparation solutions
- Expand academic and government market coverage
- Build NMR market position



APPENDIX

AGILENT TECHNOLOGIES, INC
RECONCILIATION FROM GAAP TO NON-GAAP

THREE MONTHS ENDED October 31, 2010
(Unaudited)

		Non-GAAP Adjustments													
		GAAP	Restructuring and Other Related Costs - FY 2009 Plan	Asset Impairments	Intangible Amortization	Transformational Restructuring	Business Divestitures	Varian Acquisition & Integration Costs	Varian Acquisition Related Fair Value Adjustments	Tax Sharing Settlement	Other	Adjustment for Taxes	Non-GAAP		
Orders	Change Year Over Year	32%	\$ 1,687	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 1,687	32% Change Year Over Year	
Net revenue	Change Year Over Year	35%	\$ 1,576	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 8	\$ -	\$ -	\$ -	\$ 1,584	36% Change Year Over Year	
Costs and expenses:															
Cost of products and services	Gross Margin	52.9%	742	(1)	-	(17)	(3)	-	(1)	(10)	-	(1)	-	709	55.3% Gross Margin
Research and development	As a % of Revenue	10.1%	159	(1)	-	-	(2)	-	-	-	-	1	-	157	9.9% As a % of Revenue
Selling, general and administrative	As a % of Revenue	29.9%	472	(6)	(5)	(13)	(5)	(2)	(24)	-	-	(2)	-	415	26.2% As a % of Revenue
Total costs and expenses			1,373	(8)	(5)	(30)	(10)	(2)	(25)	(10)	-	(2)	-	1,281	
Income from operations	Operating Margin	12.9%	203	8	5	30	10	2	25	18	-	2	-	303	19.1% Operating Margin
Other income (expense), net			40	-	-	-	-	(4)	-	-	(54)	(4)	-	(22)	
Income before taxes			243	8	5	30	10	(2)	25	18	(54)	(2)	-	281	
Provision for taxes	Tax rate (incl. Valuation Allowance)	-20%	(49)	-	-	-	-	-	-	-	-	-	102	53	Tax rate (incl. Valuation Allowance) 19%
Net income	Net Margin	18.5%	\$ 292	\$ 8	\$ 5	\$ 30	\$ 10	\$ (2)	\$ 25	\$ 18	\$ (54)	\$ (2)	\$ (102)	\$ 228	14.4% Net Margin

Net income per share - Basic and Diluted:

Basic	\$ 0.84	\$ 0.02	\$ 0.01	\$ 0.09	\$ 0.03	\$ (0.01)	\$ 0.07	\$ 0.05	\$ (0.16)	\$ (0.01)	\$ (0.27)	\$ 0.66
Diluted	\$ 0.83	\$ 0.02	\$ 0.01	\$ 0.09	\$ 0.03	\$ (0.01)	\$ 0.07	\$ 0.05	\$ (0.15)	\$ (0.01)	\$ (0.28)	\$ 0.65

Weighted average shares used in computing net income per share:

Basic	346	346	346	346	346	346	346	346	346	346	346	346
Diluted	352	352	352	352	352	352	352	352	352	352	352	352

The preliminary reconciliation from GAAP to Non-GAAP net income is estimated based on our current information.

AGILENT TECHNOLOGIES, INC
RECONCILIATION FROM GAAP TO NON-GAAP

TWELVE MONTHS ENDED October 31, 2010
(Unaudited)

		Non-GAAP Adjustments															
			Restructuring and Other Related Costs - FY 2009 Plan	Asset Impairments	Intangible Amortization	Transformational Restructuring	Litigation Settlement	Business Divestitures	Acquisition & Integration Costs	Varian Acquisition Related Fair Value Adjustments	Acceleration of Share-Based Compensation Expense Related to Workforce Reduction	Tax Sharing Settlement	Other	Adjustment for Taxes	Non-GAAP		
(In millions, except per share amounts)																	
Orders	Change Year Over Year	28%	\$ 5,744	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 5,744	28% Change Year Over Year
Net revenue	Change Year Over Year	21%	\$ 5,444	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 19	\$ -	\$ -	\$ -	\$ -	\$ 5,463	22% Change Year Over Year
Costs and expenses:																	
Cost of products and services	Gross Margin	53.8%	2,514	(8)	(5)	(49)	(15)	-	(1)	(32)	-	-	(1)	-	2,403	56.0% Gross Margin	
Research and development	As a % of Revenue	11.2%	612	(3)	-	(7)	-	-	-	-	-	-	(1)	-	601	11.0% As a % of Revenue	
Selling, general and administrative	As a % of Revenue	32.2%	1,752	(53)	(14)	(28)	(17)	-	(13)	(101)	-	(1)	-	(2)	1,523	27.9% As a % of Revenue	
Total costs and expenses			4,878	(64)	(19)	(77)	(39)	-	(13)	(102)	(32)	(1)	-	(4)	-	4,527	
Income from operations	Operating Margin	10.4%	566	64	19	77	39	-	13	102	51	1	-	4	-	936	17.1% Operating Margin
Other income (expense), net			126	-	-	-	(8)	(129)	-	-	-	(54)	1	-	(64)		
Income before taxes			692	64	19	77	39	(8)	(116)	102	51	1	(54)	5	-	872	
Provision for taxes	Tax rate (incl. Valuation Allowance)	1%	8	-	-	-	-	-	-	-	-	-	-	158	166	Tax rate (incl. Valuation Allowance) 19%	
Net income	Net Margin	12.6%	\$ 684	\$ 64	\$ 19	\$ 77	\$ 39	\$ (8)	\$ (116)	\$ 102	\$ 51	\$ 1	\$ (54)	\$ 5	\$ (158)	\$ 706	12.9% Net Margin

Net income per share - Basic and Diluted:

Basic	\$ 1.97	\$ 0.18	\$ 0.05	\$ 0.22	\$ 0.11	\$ (0.02)	\$ (0.33)	\$ 0.29	\$ 0.15	\$ -	\$ (0.16)	\$ 0.01	\$ (0.45)	\$ 2.03
Diluted	\$ 1.94	\$ 0.18	\$ 0.05	\$ 0.22	\$ 0.11	\$ (0.02)	\$ (0.33)	\$ 0.29	\$ 0.14	\$ -	\$ (0.15)	\$ 0.01	\$ (0.44)	\$ 2.00

Weighted average shares used in computing net income per share:

Basic	347	347	347	347	347	347	347	347	347	347	347	347	347	347
Diluted	353	353	353	353	353	353	353	353	353	353	353	353	353	353

The preliminary reconciliation from GAAP to Non-GAAP net income is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
RECONCILIATION OF ROIC
(In millions)
(Unaudited)
PRELIMINARY

	LSG Q4'10	CAG Q4'10	EMG Q4'10	Agilent Q4'10	LSG Q4'09	CAG Q4'09	EMG Q4'09	Agilent Q4'09	LSG Q3'10	CAG Q3'10	EMG Q3'10
Numerator:											
Non-GAAP income (loss) from operations	\$ 62	\$ 86	\$ 153	\$ 303	\$ 47	\$ 62	\$ 40	\$ 150	\$ 56	\$ 69	\$ 127
Less:											
Taxes and Other (income)/expense	10	17	27	57	8	13	3	26	11	14	24
Segment return	52	69	126	246 ^(a)	39	49	37	124 ^(a)	45	55	103
Segment return annualized	\$ 208	\$ 276	\$ 504	\$ 984	\$ 156	\$ 196	\$ 148	\$ 496	\$ 181	\$ 220	\$ 412
Denominator:											
Segment assets ^(b)	\$ 1,564	\$ 1,635	\$ 2,245	\$ 5,442	\$ 1,019	\$ 463	\$ 2,084	\$ 3,566	\$ 1,493	\$ 1,592	\$ 2,191
Less:											
Net current liabilities ^(c)	327	262	660	1,250	206	137	578	927	290	239	576
Invested capital	\$ 1,237	\$ 1,373	\$ 1,585	\$ 4,192	\$ 813	\$ 326	\$ 1,506	\$ 2,639	\$ 1,203	\$ 1,353	\$ 1,615
Average invested capital	\$ 1,220	\$ 1,363	\$ 1,600	\$ 4,182	\$ 815	\$ 332	\$ 1,538	\$ 2,683	\$ 1,244	\$ 1,306	\$ 1,645
ROIC	17%	20%	32%	24%	19%	59%	10%	18%	15%	17%	25%

Historical amounts are reclassified to conform with current period presentation

ROIC calculation: (annualized current quarter segment return)/(average of the two most recent quarter-end balances of Segment Invested Capital)

^(a) Agilent return is equal to non-GAAP net income from operations of \$228 million plus net interest expense after tax of \$18 million for Q4'10, and \$111 million plus net interest expense after tax of \$13 million for Q4'09. Please see "Non-GAAP Net Income and Diluted EPS Reconciliations" for a reconciliation of non-GAAP net income from operations to GAAP income (loss) from operations.

^(b) Segment assets consist of inventory, accounts receivable, property plant and equipment, gross goodwill and other intangibles, deferred taxes and allocated corporate assets.

^(c) Includes accounts payable, employee compensation and benefits, deferred revenue, other accrued liabilities and allocated corporate liabilities.

Return on Invested Capital (ROIC) is a non-GAAP measure that management believes provides useful supplemental information for management and the investor. ROIC is a tool by which we track how much value we are creating for our shareholders. Management uses ROIC as a performance measure for our businesses, and our senior managers' compensation is linked to ROIC improvements as well as other performance criteria. We believe that ROIC provides our management with a means to analyze and improve their business, measuring segment profitability in relation to net asset investments. We acknowledge that ROIC may not be calculated the same way by every company. We compensate for this limitation by monitoring and providing to the reader a full GAAP income statement and balance sheet.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary reconciliation of ROIC is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.
LIFE SCIENCES INFORMATION**

(Unaudited)

(In millions)	FY 2010				
	Q1	Q2	Q3	Q4	Total
Orders	\$ 336	\$ 331	\$ 391	\$ 468	\$ 1,526
Net revenue	\$ 340	\$ 334	\$ 374	\$ 431	\$ 1,479
Gross margin	54.4%	55.0%	53.8%	51.2%	53.5%
Income from operations	\$ 55	\$ 48	\$ 56	\$ 62	\$ 221

	FY 2009				
	Q1	Q2	Q3	Q4	Total
Orders	\$ 307	\$ 287	\$ 288	\$ 352	\$ 1,234
Net revenue	\$ 309	\$ 298	\$ 293	\$ 319	\$ 1,219
Gross margin	54.5%	54.7%	53.2%	54.4%	54.2%
Income from operations	\$ 44	\$ 44	\$ 39	\$ 47	\$ 174

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to the amortization of intangibles, the impact of restructuring charges, the acquisition of Varian, Inc., and the sale of our businesses.

In general, recorded orders represent firm purchase commitments from our customers with established terms and conditions for products and services that will be delivered within six months.

Historical amounts have been reclassified to conform with current period presentation.

AGILENT TECHNOLOGIES, INC.
CHEMICAL ANALYSIS INFORMATION

(Unaudited)

(In millions)	FY 2010				
	Q1	Q2	Q3	Q4	Total
Orders	\$ 242	\$ 231	\$ 350	\$ 401	\$ 1,224
Net revenue	\$ 244	\$ 238	\$ 329	\$ 389	\$ 1,200
Gross margin	55.1%	54.5%	52.7%	52.5%	53.5%
Income from operations	\$ 67	\$ 57	\$ 69	\$ 86	\$ 279
	FY 2009				
	Q1	Q2	Q3	Q4	Total
Orders	\$ 216	\$ 194	\$ 205	\$ 238	\$ 853
Net revenue	\$ 216	\$ 200	\$ 203	\$ 225	\$ 844
Gross margin	55.1%	53.3%	53.8%	55.1%	54.4%
Income from operations	\$ 57	\$ 45	\$ 52	\$ 62	\$ 216

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to the amortization of intangibles, the impact of restructuring charges, the acquisition of Varian, Inc., and the sale of our businesses.

In general, recorded orders represent firm purchase commitments from our customers with established terms and conditions for products and services that will be delivered within six months.

Historical amounts have been reclassified to conform with current period presentation.

AGILENT TECHNOLOGIES, INC.
ELECTRONIC MEASUREMENT INFORMATION

(Unaudited)

(In millions)	FY 2010				
	Q1	Q2	Q3	Q4	Total
Orders	\$ 642	\$ 784	\$ 750	\$ 818	\$ 2,994
Net revenue	\$ 629	\$ 699	\$ 692	\$ 764	\$ 2,784
Gross margin	57.3%	58.8%	58.8%	58.7%	58.4%
Income from operations	\$ 58	\$ 100	\$ 127	\$ 153	\$ 438
	FY 2009				
	Q1	Q2	Q3	Q4	Total
Orders	\$ 592	\$ 545	\$ 578	\$ 684	\$ 2,399
Net revenue	\$ 641	\$ 593	\$ 561	\$ 623	\$ 2,418
Gross margin	53.9%	50.4%	53.1%	56.5%	53.5%
Income (loss) from operations	\$ (6)	\$ (22)	\$ (11)	\$ 40	\$ 1

Income (loss) from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income (loss) from operations of our reporting segments exclude, among other things, charges related to the amortization of intangibles, the impact of restructuring charges, the acquisition of Varian, Inc., and the sale of our businesses.

In general, recorded orders represent firm purchase commitments from our customers with established terms and conditions for products and services that will be delivered within six months.

Historical amounts have been reclassified to conform with current period presentation.

AGILENT TECHNOLOGIES, INC.
NET CASH
(In millions)
(Unaudited)
PRELIMINARY

	<u>Q4'10</u>	<u>Q4'09</u>
Cash and cash equivalents	\$ 2,649	\$ 2,479
Restricted cash and cash equivalents	1,550	1,566
Investments - debt securities	-	36
Short-term debt	(1,501)	-
Long-term debt	-	(1,516)
Senior notes, par value	(2,100)	(1,350)
Total Net Cash	\$ 598	\$ 1,215

The preliminary reconciliation of net cash is estimated based on our current information.

Management believes this metric provides useful information to investors about the Company's overall liquidity and financial position. Net Cash is a measure at a point in time and does not reflect the Company's future financial prospects or liquidity.

AGILENT TECHNOLOGIES, INC.
REVENUE RECONCILIATION
(In millions)
(Unaudited)
PRELIMINARY

	<u>Q4'10</u>	<u>Q4'09</u>	<u>Percent Inc/(Dec)</u>
GAAP Revenue	\$ 1,576	\$ 1,167	35%
Varian acquisition fair value adjustments	8	-	
Non-GAAP Revenue	\$ 1,584	\$ 1,167	
Less revenue from acquisition and divestitures included in segment results	(193)	(65)	
Non-GAAP Revenue, adjusted	\$ 1,391	\$ 1,102	26%

Revenues, excluding the impact of the Varian acquisition and recent divestitures, are a non-GAAP measure and are defined to exclude the fair value adjustment to acquisition related deferred revenue balances for the Varian acquisition and exclude the impacts of the Varian acquisition and the divestitures of our Network Systems and Hycor businesses.

Management believes that this measure provides useful information to investors by reflecting an additional way of viewing aspects of Agilent's operations that, when reconciled to the corresponding GAAP measures, help our investors to better identify underlying growth trends in our business and facilitate easier comparisons of our revenue performance with prior and future periods and to our peers. We excluded the effect of the Varian acquisition and recent divestitures because the nature, size and number of these can vary dramatically from period to period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.